^
Association details:
| Biomarker: | PD-1 overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | tebotelimab (MGD013) (PD1 inhibitor, LAG-3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3022 A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Published date:
11/04/2020
Excerpt:
...Analyses of available pre-treatment tumor biopsy samples corresponding to responding pts demonstrated relatively high levels of LAG-3, PD-1, and PD-L1 by IHC...Following MGD013 treatment, serum IFN-γ markedly increased to >140-fold above baseline…
